finance
Apparel Retailers May See $13 Billion Annual Spending Increase from GLP-1 Weight Loss Drugs
Equity research firm Bernstein estimates that GLP-1 drugs, used by millions for weight loss, could drive up to $13 billion in additional annual spending at apparel retailers. Users of these medications are purchasing new clothing to fit their changed body sizes. The projection highlights potential shifts in consumer spending patterns tied to health treatments.
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Millions of individuals using GLP-1 drugs for weight loss have begun purchasing new apparel from retailers to accommodate their reduced body sizes. GLP-1 drugs, such as semaglutide found in medications like Ozempic and Wegovy, are approved for treating type 2 diabetes and obesity. These treatments have gained widespread use, leading to significant weight reduction in many patients.
Equity research firm Bernstein projects that this trend could result in up to $13 billion in additional annual spending for apparel retailers. The estimate accounts for purchases of smaller-sized clothing by users who have lost weight. U.S.
market, where GLP-1 prescriptions have surged in recent years.
receptor agonists mimic hormones that regulate blood sugar and appetite, promoting weight loss as a side effect.
The drugs were initially developed for diabetes management but have seen expanded use for obesity treatment following FDA approvals. As of 2023, millions of Americans have adopted these medications, with prescriptions continuing to rise amid growing awareness of their weight loss benefits.
The shift in body size among users creates a practical need for wardrobe updates, affecting clothing consumption.
Retailers in the apparel sector, including department stores and specialty chains, stand to benefit from this demand. Bernstein's report, based on market data and consumer surveys, underscores how health innovations can influence retail sectors.
This projected spending boost represents a notable opportunity for apparel companies facing other economic pressures, such as inflation and shifting consumer preferences.
U.S. apparel sales, depending on baseline market volumes. Affected stakeholders include apparel manufacturers, retailers, and supply chain partners who may need to adjust inventory for smaller sizes. Looking ahead, the sustainability of this trend depends on the ongoing adoption of GLP-1 drugs and their long-term use by patients.
